Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given an average recommendation of “Moderate Buy” by the four ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $70.67.

INO has been the subject of several recent analyst reports. StockNews.com lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. HC Wainwright restated a “neutral” rating and set a $15.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday. Finally, Stephens initiated coverage on Inovio Pharmaceuticals in a research report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 target price for the company.

Inovio Pharmaceuticals Trading Down 2.7 %

Shares of INO stock opened at $11.00 on Monday. Inovio Pharmaceuticals has a 12-month low of $3.89 and a 12-month high of $14.75. The stock’s 50-day moving average price is $9.88 and its 200-day moving average price is $22.59. The stock has a market capitalization of $285.01 million, a price-to-earnings ratio of -3.43 and a beta of 0.90.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Monday, May 13th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by ($0.23). Inovio Pharmaceuticals had a negative return on equity of 88.13% and a negative net margin of 16,238.91%. During the same period in the prior year, the firm earned ($1.92) earnings per share. As a group, research analysts predict that Inovio Pharmaceuticals will post -4.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Inovio Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 115,361 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 6,148 shares in the last quarter. Keystone Financial Group boosted its holdings in shares of Inovio Pharmaceuticals by 11.7% in the fourth quarter. Keystone Financial Group now owns 122,737 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 12,840 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Inovio Pharmaceuticals in the first quarter valued at about $1,482,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.